|
EMV Capital PLC on Wednesday said its loss widened during 2024 as income fell, though the firm remains cautiously optimistic in its outlook. The life sciences investor said its pretax loss widened to £3.7 million in 2024 from £2.9 million in 2023, as total income declined 24% to £2.9 million from £3.8 million. Other operating income was reduced by 79% to £474,000 from £2.3 million, while cost of sales increased 64% to £360,000 from £219,000. Total assets under management at the year-end was £98.5 million, up 33% from £74.0 million a year prior. AuM at May 31 stood at £103 million. ‘The directors believe the group is well positioned to withstand current macroeconomic headwinds and capitalise on a future market recovery, particularly as interest grows in several of the sectors in which we invest. The directors believe that the next ’cohort’ of outsized venture returns will come from companies in these sectors, driven by redirections of investment and [mergers & acquisitions] flows,’ said Chief Executive Officer Ilian Iliev. ‘Although the current climate for investment and exits remains difficult both in the UK and globally, we see meaningful opportunity amid the disruption. We remain cautious but are confident in our outlook, underpinned by a resilient investment model and operating platform. We have a differentiated strategy that allows us to unlock value from our existing portfolio and build our position further.’ Shares in EMV Capital were down 3.7% at 39.00 pence each in London on Wednesday afternoon. The stock is down 43% over the past year. CEO Iliev continued: ‘Most encouragingly, several of our holdings are approaching inflection points, with the potential to deliver significant investment returns. Looking ahead, we believe the coming years will bring further momentum, growth, and strategic progress, cementing EMV Capital as a leading player in deep tech and life sciences, and delivering long-term value to our shareholders.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
